TSW
ALXN

Thompson Siegel & Walmsley’s Alexion Pharmaceuticals ALXN Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-42,986
Closed -$7.9M – 758
2021
Q2 		$7.9M Sell
42,986
-536,694
-93% -$92.1M 0.11% 159
2021
Q1 		$88.6M Sell
579,680
-79,752
-12% -$12.3M 1.26% 19
2020
Q4 		$103M Buy
659,432
+20,947
+3% +$2.69M 1.65% 7
2020
Q3 		$73.1M Buy
638,485
+53,031
+9% +$5.72M 1.42% 15
2020
Q2 		$65.7M Buy
585,454
+33,976
+6% +$3.61M 1.32% 17
2020
Q1 		$49.5M Buy
+551,478
New +$54.1M 1.18% 29

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return